Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.09
- Piotroski Score 2.00
- Grade Equal-Weight
- Symbol (AGLE)
- Company Aeglea BioTherapeutics, Inc.
- Price $12.01
- Changes Percentage (6.66%)
- Change $0.75
- Day Low $10.69
- Day High $12.34
- Year High $24.00
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$74.15
- Trailing P/E Ratio -0.16196898179366
- Forward P/E Ratio -0.16196898179366
- P/E Growth -0.16196898179366
- Net Income $-83,815,000
Income Statement
Quarterly
Annual
Latest News of AGLE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Investors in Eagle Eye Solutions Group (LON:EYE) have seen strong returns of 188% over the past five years
Investing in stocks can result in losing all your money or gaining over 100%. Eagle Eye Solutions Group plc stock has seen an impressive 188% increase in the last five years. Analyzing its fundamental...
By Yahoo! Finance | 10 hours ago -
Eagles seek 7th straight win while Rams try to keep pace in crowded NFC West race
In the last meeting, Eagles beat Rams 23-14. RB Saquon Barkley impressed with 198 scrimmage yards against Washington. Rookie S Kam Kinchens stood out with 8 tackles, 1 INT, and a forced fumble....
By AP NEWS | 17 hours ago -
Rare "double eagle" coin sells for $1.4 million at auction
A rare 1870 $20 "double eagle" gold coin sold for $1.44 million at a California auction. With only 40-50 known to exist, the highest-graded coin was part of the Bernard Richards collection....
By Newsweek | 1 day ago
